# Study of ZG005 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06927687/  
OnCo record `nct06927687` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ZG005 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, active and no longer recruiting.

## Summary

Study of ZG005 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06927687 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 50 participants enrolled, started 2025-06-13 and due to reach its primary completion in 2027-05. Interventions recorded: ZG005 for Injection.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06927687
- Phase: 2
- Setting: A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06927687: https://clinicaltrials.gov/study/NCT06927687

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06927687.json